M&A - Nuvation Bio Inc.

Form Type: 10-Q

Filing Date: 2025-05-07

Corporate Action: Acquisition

Type: Update

Accession Number: 000095017025065712

Filing Summary: This quarterly report summarizes Nuvation Bio Inc.'s financial performance for the period ending March 31, 2025. The company reported total revenue of $3,084,000 with operating expenses amounting to $59,994,000, leading to a net loss of $53,236,000. Current assets have decreased from $526,255,000 to $475,567,000 from the previous quarter. The liabilities include a total of $73,029,000, while stockholders' equity stands at $419,460,000. Additionally, the company finalized an acquisition of AnHeart Therapeutics on April 9, 2024, and highlighted various financial risks and uncertainties in the management discussion. Forward-looking statements project potential for increased revenue, provided they can navigate challenges including market competition and securing further collaborations or funding. The detailed balance sheet shows active management of current liabilities and continued investment in growth areas such as research and development.

Form Type: 10-K

Filing Date: 2025-03-06

Corporate Action: Acquisition

Type: Update

Accession Number: 000095017025034903

Filing Summary: Nuvation Bio Inc. filed its annual 10-K report, detailing operations and financial performance for the fiscal year ending December 31, 2024. The report emphasizes that the company has made significant advances in its clinical pipeline, particularly concerning its lead candidate, taletrectinib, for which the FDA has granted priority review status. The financial data indicates that as of mid-2024, the market value of voting common stock held by non-affiliates was approximately $522.74 million. The report highlights the risks surrounding clinical trials, fundraising, and regulatory approvals essential for commercialization. Furthermore, the recent acquisition of AnHeart may present integration challenges, affecting ongoing operations and management focus. Lastly, the company acknowledges the need for substantial funding going forward while being exposed to various operational risks, including competition, regulatory compliance, and potential product liability. The report underscores the speculative nature of investing in their securities due to these uncertainties.

Form Type: 8-K

Filing Date: 2025-02-12

Corporate Action: Merger

Type: Update

Accession Number: 000119312525025099

Filing Summary: On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the Company after achieving significant milestones. These include obtaining the approval from China’s National Medical Products Administration for taletrectinib aimed at advanced ROS1-positive non-small cell lung cancer, and the U.S. FDA's acceptance and priority review of the New Drug Application for the same drug. Following these achievements and the successful integration of AnHeart Therapeutics into Nuvation Bio after their merger, the need for Dr. Wang’s role as CEO of AnHeart Therapeutics ceased. Additionally, Dr. Wang resigned from the Board of Directors, effective February 11, 2025. His departure was not due to any disagreements with the Company, and the Company expressed gratitude for his contributions.